CNBC’s Meg Tirrell sits down with Gilead CEO Daniel O’Day amid the American Society of Clinical Oncology conference in Chicago to discuss the company’s latest data surrounding its cancer drug Trodelvy.
You May Also Like
About the Author: Chaz Cutler
My name is Chasity. I love to follow the stock market and financial news!